ERBB2 and breast cancer: We therefore conducted a 2-year post-marketing observational study to mainly assess CIPN incidence by severity and risk factors following eribulin treatment in patients with HER2-negative inoperable or recurrent breast cancer, regardless of the patient’s line therapy status.